Platelet and white blood cells in severity of sickle cell diseases;Recuento de plaquetas y glóbulos blancos en la severidad de la enfermedad de células falciformes

Prensa Medica Argentina

Volumn 100, Issue 1, 2014, Pages 49-56

  Helvaci, Mehmet Rami ^a   Aydogan, Fusun ^a   Sevinc, Alper ^b   Camci, Celaletdin ^b   Dilek, Imdat ^c  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902668650     PISSN: 0032745X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
2. Helvaci MR, Kaya H, Gundogdu M. Association of increased triglyceride levels in metabolic syndrome with coronary artery disease. Pak J Med Sci 2010; 26: 667-672.
3. Helvaci MR, Kaya H, Borazan A, Ozer C, Seyhanli M, Yalcin A. Metformin and parameters of physical health. Intern Med 2008; 47: 697-703.
4. Helvaci MR, Kaya H, Seyhanli M, Yalcin A. White coat hypertension in definition of metabolic syndrome. Int Heart J 2008; 49: 449-457.
5. Helvaci MR, Kaya H, Seyhanli M, Cosar E. White coat hypertension is associated with a greater all-cause mortality. J Health Sci 2007; 53: 156-160.
6. Helvaci MR, Aydin LY, Aydin Y. Chronic obstructive pulmonary disease may be one of the terminal end points of metabolic syndrome. Pak J Med Sci 2012; 28: 376-379.
7. Helvaci MR, Erden ES, Aydin LY. Atherosclerotic background of chronic obstructive pulmonary disease in sickle cell patients. HealthMED 2013; 7: 484-488.
8. Helvaci MR, Aydin Y, Ayyildiz O. Clinical severity of sickle cell anemia alone and sickle cell diseases with thalassemias. HealthMED 2013; 7: 2028-2033.
9. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2010. Global initiative for chronic obstructive lung disease (GOLD).
10. Mankad VN, Williams JP, Harpen MD, Manci E, Longenecker G, Moore RB, et al. Magnetic resonance imaging of bone marrow in sickle cell disease: clinical, hematologic, and pathologic correlations. Blood 1990; 75: 274-283.
11. Schamroth L. Personal experience. S Afr Med J 1976; 50: 297-300.
12. Vandemergel X, Renneboog B. Prevalence, aetiologies and significance of clubbing in a department of general internal medicine. Eur J Intern Med 2008; 19: 325-329.
13. Helvaci MR, Aydin Y, Ayyildiz O. Hydroxyurea may prolong survival of sickle cell patients by decreasing frequency of painful crises. HealthMED 2013; 7: 2327-2332.
14. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-1644.
15. Mathers CD, Sadana R, Salomon JA, Murray CJ, Lopez AD. Healthy life expectancy in 191 countries, 1999. Lancet 2001; 357: 1685-1691.
16. Helvaci MR, Ayyildiz O, Gundogdu M. Gender differences in severity of sickle cell diseases in non-smokers. Pak J Med Sci 2013; 29: 1050-1054.
17. Parfrey NA, Moore W, Hutchins GM. Is pain crisis a cause of death in sickle cell disease? Am J Clin Pathol 1985; 84: 209-212.
18. Helvaci MR, Ayyildiz O, Gundogdu M. Painful crises and survival of sickle cell patients. Health MED (in press).
19. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342: 83-89.
20. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992; 120: 360-366.
21. Cole TB, Sprinkle RH, Smith SJ, Buchanan GR. Intravenous narcotic therapy for children with severe sickle cell pain crisis. Am J Dis Child 1986; 140: 1255-1259.
22. Miller BA, Platt O, Hope S, Dover G, Nathan DG. Influence of hydroxyurea on fetal hemoglobin production in vitro. Blood 1987; 70: 1824-1829.
23. Platt OS Is there treatment for sickle cell anemia? N Engl J Med 1988; 319: 1479-1480.
24. Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol 1997; 34: 15-21.
25. Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi CE, et al. NIH consensus development statement on hydroxyurea treatment for sickle cell disease. NIH Consens State Sci Statements 2008; 25: 1-30.
26. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 285-293.
27. Campion SN, Davenport SJ, Nowland WS, Cappon GD, Bowman CJ, Hurtt ME. Sensitive windows of skeletal development in rabbits determined by hydroxyurea exposure at different times throughout gestation. Birth Defects Res B Dev Reprod Toxicol 2012; 95: 238-249.
28. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 1996; 75: 300-326.
29. Helvaci MR, Ayyildiz O, Gundogdu M. Hydroxyurea therapy and parameters of health in sickle cell patients. HealthMED (in press).
30. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651.
31. Lebensburger JD, Miller ST, Howard TH, Casella JF, Brown RC, Lu M, et al; BABY HUG Investigators. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatr Blood Cancer 2012; 59: 675-678.